Invention Grant
![Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function](/docs/US/2022-08-09/US11407748B2/abs.jpg.600x600.jpg)
- Patent Title: Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function
-
Application No.: US16753613Application Date: 2018-10-04
-
Publication No.: US11407748B2Publication Date: 2022-08-09
- Inventor: Shinji Nakamura , Satoshi Mikami , Tomoaki Hasui , Tohru Yamashita , Shinji Morimoto , Hidekazu Tokuhara , Norio Oyabu , Masami Yamada , Atsuko Ochida , Kazuaki Takami , Xin Liu
- Applicant: Takeda Pharmaceutical Company Limited
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- Priority: JPJP2017-195904 20171006
- International Application: PCT/JP2018/037282 WO 20181004
- International Announcement: WO2019/070043 WO 20190411
- Main IPC: A61K31/519
- IPC: A61K31/519 ; C07D471/04 ; C07D487/04 ; A61K9/20 ; C07D519/00
![Substituted pyrido[1,2-a]pyrimidines and pyrazino[1,2-a]pyrimidines for enhancing AMPA receptor function](/abs-image/US/2022/08/09/US11407748B2/abs.jpg.150x150.jpg)
Abstract:
The present invention aims to provide a heterocyclic compound having an AMPA receptor potentiator effect, which is expected to be useful as an agent for the prophylaxis or treatment of depression, Alzheimer's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and the like.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.
Public/Granted literature
- US20200270243A1 HETEROCYCLIC COMPOUND Public/Granted day:2020-08-27
Information query
IPC分类:
